This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frystyk, J. Articles by Zethelius, B. Search for Related Content PubMed PubMed Citation Articles by Frystyk, J. Articles by Zethelius, B. Related Collections Cardiovascular Endocrinology Obesity

Serum Adiponectin Is a Predictor of Coronary Heart Disease: A Population-Based 10-Year Follow-Up Study in Elderly Men

The Medical Research Laboratories, Clinical Institute, Aarhus University Hospital (J.F., A.F.), DK-8000 Aarhus, Denmark; and Departments of Medical Sciences (C.B.) and Public Health and Caring Sciences/Geriatrics (B.Z.), Uppsala University, and Uppsala Clinical Research Centre (K.J., L.B.), 75125 Uppsala, Sweden

Address all correspondence and requests for reprints to: Dr. Jan Frystyk, Medical Research Laboratories, Aarhus University Hospital, Nørrebrogade 44, DK-8000 Aarhus C, Denmark. E-mail: jan{at}frystyk.dk.

Context: Cross-sectional and nested case-control studies indicate a relationship between adiponectin, obesity, and coronary heart disease (CHD).

Objective: Our objective was to investigate whether adiponectin could predict CHD in a population-based cohort of elderly men.

Design and Setting: From 1991–1995 a baseline investigation was carried out in 832 healthy men aged 70 yr in the Uppsala Longitudinal Study of Adult Men (ULSAM study). They were followed up to 10.4 yr using Swedish national registry data. The baseline investigation included anthropometry, blood pressure, smoking, serum lipids, a euglycemic insulin clamp, and fasting serum adiponectin.

Main Outcome Measures: Main outcome measures were defined as death or first-time hospitalization for CHD (n = 116), recorded in the Cause of Death Registry or in the Hospital-Discharge Registry of the National Board of Health and Welfare, Sweden. Associations were analyzed using Cox’s proportional hazards regression, presented as hazard ratios (HR) with 95% confidence intervals (CI) for 1 SD increase in the predictor variable.

Results: In a multivariable analysis including total cholesterol (HR, 1.24; CI, 1.02–1.50), high-density lipoprotein cholesterol (HR, 0.72; CI, 0.58–0.89), smoking (HR, 1.39; CI, 0.91–2.14), and systolic blood pressure (HR, 1.26; CI, 1.05–1.52), serum adiponectin was associated with lower risk for CHD (HR, 0.81; CI, 0.66–0.99). The association was independent of BMI and remained significant after adjustment for insulin sensitivity index.

Conclusions: In this population-based cohort of healthy men, elevated serum levels of adiponectin were associated with a lower risk for CHD. Importantly, the association between adiponectin and CHD was independent of other well-known risk factors.

This article has been cited by other articles:

				K. Michaelsson, L. Lind, J. Frystyk, A. Flyvbjerg, R. Gedeborg, C. Berne, B. Zethelius, H. Mallmin, S. Soderberg, and H. Melhus Serum Adiponectin in Elderly Men Does Not Correlate with Fracture Risk J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 4041 - 4047. [Abstract] [Full Text] [PDF]

				J. R. Kizer, J. I. Barzilay, L. H. Kuller, and J. S. Gottdiener Adiponectin and Risk of Coronary Heart Disease in Older Men and Women J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3357 - 3364. [Abstract] [Full Text] [PDF]

				G. Maiolino, M. Cesari, D. Sticchi, M. Zanchetta, L. Pedon, K. Antezza, A. C. Pessina, and G. P. Rossi Plasma Adiponectin for Prediction of Cardiovascular Events and Mortality in High-Risk Patients J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3333 - 3340. [Abstract] [Full Text] [PDF]

				E. D. Abel, S. E. Litwin, and G. Sweeney Cardiac Remodeling in Obesity Physiol Rev, April 1, 2008; 88(2): 389 - 419. [Abstract] [Full Text] [PDF]

				J. M. Dekker, T. Funahashi, G. Nijpels, S. Pilz, C. D. A. Stehouwer, M. B. Snijder, L. M. Bouter, Y. Matsuzawa, I. Shimomura, and R. J. Heine Prognostic Value of Adiponectin for Cardiovascular Disease and Mortality J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1489 - 1496. [Abstract] [Full Text] [PDF]

				P. M. Nilsson Is adiponectin and its genetic regulators useful or not for prediction of carotid intima-media thickness and coronary heart disease? Eur. Heart J., February 1, 2008; 29(3): 293 - 295. [Full Text] [PDF]

				M. Matsumoto, S. Ishikawa, and E. Kajii Association of Adiponectin With Cerebrovascular Disease: A Nested Case-Control Study Stroke, February 1, 2008; 39(2): 323 - 328. [Abstract] [Full Text] [PDF]

				V. Beauloye, F. Zech, H. Tran Thi Mong, P. Clapuyt, M. Maes, and S. M. Brichard Determinants of Early Atherosclerosis in Obese Children and Adolescents J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3025 - 3032. [Abstract] [Full Text] [PDF]

				C. S. Johnston, B. L. Beezhold, B. Mostow, and P. D. Swan Plasma Vitamin C Is Inversely Related to Body Mass Index and Waist Circumference but Not to Plasma Adiponectin in Nonsmoking Adults J. Nutr., July 1, 2007; 137(7): 1757 - 1762. [Abstract] [Full Text] [PDF]

				C. Menzaghi, V. Trischitta, and A. Doria Genetic Influences of Adiponectin on Insulin Resistance, Type 2 Diabetes, and Cardiovascular Disease Diabetes, May 1, 2007; 56(5): 1198 - 1209. [Abstract] [Full Text] [PDF]